A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

Biocompatible stiffness enhanced pliable electrically conductive filaments configured for contact with living tissue and electrical communication with such tissue. The pliability of the filaments allows the distal end of the filaments to remain at the original site of penetration into the tissue despite the movement of the tissue relative to their surrounding environment. To temporarily stiffen the filaments, a soluble stiffness enhancing coating is disposed over the filaments. The coating may be in the form of a liquid which dries to a solid state after being applied to the filaments and renders the filaments sufficiently rigid such that under appropriate force, the filaments are capable of penetrating into dense tissue. Once in place, the stiffness enhancing coating dissolves due to contact with body fluids, the filaments, in the absence of such a coating, return to their initial pliability.

This invention describes a wound dressing product for active continuous debridement of devitalized tissues in non-healing wounds including diabetic ulcers, pressure ulcers, burn injuries and other etiologies. The present invention pertains to the principle of continuous wound debridement which makes necrotic tissue more susceptible for removal and hence enhances progressive wound healing. The dressing contains an active ingredient, such as collagenase which serves to debride wounds in-situ. In the present invention purified Collagenase (90% pure) was deposited onto several wound dressing materials. A key feature of this invention is that the activity level of the Collagenase used was substantially preserved.

The present invention provides new classes of phenolic compounds derived from hydroxyacids and tyrosol or tyrosol analogs, useful as monomers for preparation of biocompatible polymers, and the biocompatible polymers prepared from these monomeric hydroxyacid-phenolic compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processability are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric hydroxyacid-phenolic compounds and biocompatible polymers.

The subject matter of the present invention is, according to a first aspect, a dressing comprising an interface layer, characterised in that said interface layer comprises a weave coated with an elastomeric matrix comprising metformin, the salts and the complexes thereof. The subject matter of the invention is also a dressing comprising metformin, characterised in that the percentage of metformin released after 72 hours is between 40 and 100% of the quantity of metformin inserted in the dressing. Moreover, the subject matter of the invention is a method for producing said dressing as well as the use thereof for healing a wound.

The present invention relates to a therapeutic drug for a disease accompanied by a disorder in retinal cells or a retinal tissue, the drug including a retinal tissue, the retinal tissue being of an allogeneic origin and having a three-dimensional structure, wherein an intended patient to be given the therapeutic drug is a patient affected by a disease accompanied by a disorder of retinal cells or a retinal tissue, to be given systemically, for 1 month or more after the administration of the therapeutic drug, no immunosuppressive agent aimed at preventing graft rejection.

The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials.

Biodegradable implants comprising dopamine modulating compounds are described.

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.